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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disor-
der with multiorgan involvement and variable manifestations. 
The etiology of SLE remains unknown. However, a different 
presentation of lupus erythematosus due to certain drugs such 
as hydralazine1, procainamide1, and minocycline2 has long been 
recognized. The first reported case of hydralazine leading to 
Drug-induced Lupus Erythematosus (DILE) was published in 
1953.3 Since then, this association has been well established in 
the medical literature. However, as hydralazine is used less fre-
quently, the incidence of DILE due to hydralazine and the rec-
ognition of this association among clinicians have diminished. 
This case report and review revisits this association and reminds 
the clinicians to consider DILE when evaluating patients with 
unusual manifestations mimicking a connective tissue disease. 
CASE REPORT
A 68-year-old Caucasian male with a past medical history 
significant for gastroesophageal reflux disease, hypertension, 
obstructive sleep apnea, obesity, chronic obstructive pulmo-
nary disease (COPD), and hypothyroidism had developed 
bilateral hand arthralgia intermittently for several years. He 
presented with myalgia and fatigue in late 2013 and by late 
January 2014, his symptoms progressed with diffuse myalgia, 
polyarthralgia, fatigue, poor appetite, nocturnal low grade fe-
vers, as well as unintentional weight loss of about 30 pounds.
Subsequently, he developed pruritic dermatitis and dyspnea 
out of proportion to his baseline COPD. His wife also noticed 
onset of poor memory. He experienced two episodes of asymp-
tomatic hematuria without any known history of nephroli-
thiasis. He was admitted to an outside hospital for progressive 
dyspnea, fatigue, myalgia, polyarthralgia, hematuria, and the 
dermatitis on his upper back. Physical examination revealed a 
rash and splenomegaly. He was evaluated by specialists in he-
matology, neurology, infectious disease, and rheumatology. 
Basic labs revealed leukopenia and anemia. He had an elevated 
erythrocyte sedimentation rate of 97 and C-reactive protein of 
212 mg/L with normal creatinine kinase and aldolase. Infectious 
disease work-up included negative Epstein–Barr virus, lyme 
disease, human herpesvirus 6, cytomegalovirus, and human im-
munodeficiency virus. Cerebrospinal fluid analysis was nega-
tive including for cryptococcus, toxoplasma, and viral studies. 
Computed tomography scan (CT) of the chest, abdomen, and pel-
vis was negative except for splenomegaly. Bone marrow biopsy was 
unrevealing with normal cytogenetics. The right upper back skin 
biopsy was non-diagnostic as it did not identify eosinophils or other 
specific features of connective tissue disease but the findings were 
thought to be compatible with a “drug eruption or viral exanthem”.
Since a clear diagnosis was not made, he established care at 
our tertiary institution. He was seen in the outpatient hematol-
ogy and general internal medicine clinics after which he was re-
ferred to the rheumatology clinic. His medication list included 
hydralazine that was started about four years prior for treat-
ment of hypertension. Prior to being seen by the physicians at 
University of Kansas Hospital, he developed a new symmetrical 
erythematous, macular, small, and round dermatitis of hands 
and anterior thighs bilaterally. His laboratory evaluation was 
significant for a persistent leukopenia (white blood cells of 2.03 
x 10 9/L) and anemia (hemoglobin of 9.8 mg/dL). The renal and 
liver functions, creatine kinase, and lactate dehydrogenase were 
normal. The antinuclear antibody (ANA) was elevated at 1:640 in 
a homogenous pattern. The histone antibody was elevated. The 
anti-phospholipid antibodies were abnormal including elevated 
hexagonal lupus, Dilute Russell Viper Venom Test, IgM anti-car-
diolipin antibody, and IgM Beta 2-glycoprotein 1. His ds-DNA, 
Anti-Smith, Anti-SSA, Anti-SSB, Anti-RNP, Rheumatoid Factor, 
Anti-Centromere, Anti-SCL-70, Anti-CCP IgG, Anti-Jo-1 were 
normal. His Complement C3 and C4 were within normal limits. 
A chest x-ray showed a small left pleural effusion. Joint survey 
x-rays showed degenerative changes of the cervical spine, right 
knee, and bilateral hands. A repeat CT showed splenic auto-infarc-
tion. He was diagnosed with Drug-induced Lupus Erythematosus 
(DILE). At that time, he was prescribed a prednisone taper and hy-
dralazine was discontinued. Two months after discontinuation of 
hydralazine, he had a negative ANA and a decreasing anti-histone 
antibody. The anti-phospholipid antibody panel was negative. 
DISCUSSION 
This 68-year-old male patient’s symptoms and clinical find-
ings including laboratory abnormalities began several years after 
he first took hydralazine and resolved following its discontinu-
ation. DILE is a diagnosis of exclusion that is confirmed when 
the patient improves once the culprit drug is discontinued. A 
unique aspect of this case was the length of time after which 
the patient developed DILE while on a low dose of hydrala-
zine. Usually,  DILE develops on higher doses of hydralazine 
(greater than 200 mg/day) and sooner than was seen on our case.4
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continued.
 The incidence of the lupus syndrome induced by hydralazine 
was determined in a longitudinal study of 281 patients starting 
hydralazine for hypertension over a 51-month period.4 After three 
years of treatment with hydralazine, the incidence of the lupus 
syndrome was 6.7% (95% confidence limits 3.2-10.2%).  The in-
cidence was dose dependent, with no cases recorded in patients 
taking 50 mg daily and incidences of 5.4% with 100 mg daily and 
of 10.4% with 200 mg daily. Our patient had been prescribed hy-
dralazine 75 mg for hypertension before presenting with lupus-
like symptoms. To our knowledge, there have been no published 
case reports of DILE due to hydralazine at a dose of 75 mg daily. 
 Risk factors for development of hydralazine DILE include 
doses greater than 200 mg/day, female gender, slow hepatic 
acetylation, and immunogenetic factors.4-7 Clinical manifesta-
tions of DILE include fever, fatigue, mylagia, dermatitis, arthral-
gia, and serositis.8 DILE is generally less severe without signifi-
cant systemic involvement, such as nephritis. Both idiopathic 
systemic lupus erythematosus (SLE) and DILE develop elevated 
ANA; but anti-Smith antibody (SM), ds-DNA, and hypo-com-
plementemia rarely are observed in DILE as compared to SLE.
 Anti-histone antibodies are present in more than 95 per-
cent of patients with DILE.9 Anti-histone antibodies can also 
be seen in up to 80% of patients with idiopathic SLE, how-
ever, patients with idiopathic SLE also form a variety of oth-
er autoantibodies, including anti-Smith antibody or ds-DNA 
antibody, which are less common in drug-induced lupus. 
Management of DILE consists of discontinuation of the of-
fending agent along with supportive care and short term 
therapy of any specific manifestations with medications such 
as oral prednisone until symptomatic and clinical resolution.
CONCLUSION
 Prompt recognition of DILE is important in evaluation of 
patients with lupus like syndrome while on medications such 
as hydralazine. Distinguishing idiopathic SLE from DILE 
is very important as the intensity and duration of therapy 
and prognosis is different between the two. Hence, patients 
should be monitored closely when initiating hydralazine. 
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